May 2nd 2024
Phase 3b data support venetoclax as a treatment option in CLL for patients with or without B-cell receptor–associated kinase inhibitor treatment.
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Cross Q&A: Dosing Ponatinib in CML to Balance Efficacy and Cardiovascular Safety
Experts discuss dosing strategies and risk factors for arterial occlusive events in ponatinib treatment for chronic myeloid leukemia, emphasizing the importance of balancing disease control and patient safety.
Dosing Strategies and Disease Control With Ponatinib: The OPTIC Study
An expert explores findings of the OPTIC study, revealing optimal dosing strategies for ponatinib in CML treatment, including insights into dose reduction and patient response based on T315I mutation status.
Optimizing Ponatinib in CML: Understanding AOEs in the PACE Trial
A retrospective analysis of arterial occlusive events in the PACE trial, shedding light on risk factors and management strategies for ponatinib treatment in CML patients.
Team Introductions: CML Experts From the Fred Hutchinson Cancer Center and City of Hope
An overview of the program agenda and introduction of expert panelists from the Fred Hutchinson Cancer Center and City of Hope teams.
Small Elderly CLL Population Discontinues Venetoclax/Obinutuzumab Treatment
August 24th 2023Findings from a real-world study highlight that treatment utilization, such as agents for managing tumor lysis syndrome, appears to be more intense when older patients with chronic lymphocytic leukemia initiate treatment with venetoclax plus obinutuzumab.
Cross Q&A: Real-World Use of Low-Dose Dasatinib in CML
Following a review of data with low-dose dasatinib in chronic myeloid leukemia, key opinion leaders from the Mayo Clinic and UT Southwestern consider its role in real-world practice.
Chronic Myeloid Leukemia: Long-Term Follow-up of Low-Dose Dasatinib
In the last presentation of the session, Abhishek Mangaonkar, MBBS, details clinical trial data with low-dose dasatinib in patients with chronic myeloid leukemia.
Cross Q&A: Role of Olverembatinib in Heavily Pretreated CML
In this cross Q&A, both the Mayo Clinic and UT Southwestern teams share insight on the role of olverembatinib in relapsed/refractory chronic myeloid leukemia.
Relapsed/Refractory CLL: Key Takeaways and Ongoing Challenges
Closing out their discussion on relapsed/refractory chronic lymphocytic leukemia, key opinion leaders consider important takeaways from the indirect comparison study of acalabrutinib versus zanubrutinib and identify unmet needs in the treatment landscape.
Indirect Comparison of Acalabrutinib Versus Zanubrutinib in RR CLL: Safety Analysis
Key safety data from the indirect comparison study of acalabrutinib versus zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
Blinatumomab Improves OS/DFS in Low-Risk, Relapsed ALL Subgroup
August 6th 2023Combined with chemotherapy, blinatumomab appears tolerable and beneficial in a subgroup of pediatric patients with B-cell acute lymphoblastic leukemia in first relapse but does not yield better survival outcomes in the overall population.
Olverembatinib Study in Patients With Heavily Pretreated Chronic Myeloid Leukemia
A comprehensive review of chronic myeloid leukemia olverembatinib data led by expert Kebede Begna, MD, from the Mayo Clinic team.
Cross Q&A: Arterial Occlusive Events With Ponatinib in the PACE Trial
Following a review of the retrospective analysis of PACE, experts reflect on its importance in understanding the risk of arterial occlusive events with ponatinib.